Novartis AG is aiming to launch 10 potential blockbusters by 2020 but for the moment, the Swiss major is reaping the benefits from an established big seller – Cosentyx (secukinumab) – which is continuing to grow at an impressive rate.
Speaking at Novartis' annual press conference in Basel on Jan. 30, chief executive Vas Narasimhan highlighted how much of a...








